Dina Mofed

Dr. Dina Mofed


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KMKhaled O. Mohamed
Khaled O. Mohamed
YNYassin Nissan
Yassin Nissan
AEAfaf A. El-Malah
Afaf A. El-Malah
WAWafaa A. Ahmed
Wafaa A. Ahmed
DMDina Mofed
Dina Mofed
MMMohamed A. Motaleb
Mohamed A. Motaleb

7 October 2022 in Molecular Biology Reports
Verified
Journal Article
Open access
PDF file
DMDina Mofed
Dina Mofed
Jihad Ibrahim AbdelmonemJihad Ibrahim Abdelmonem
Jihad Ibrahim Abdelmonem
SSSalwa Sabet
Salwa Sabet
ABAhmed A Baiomy
Ahmed A Baiomy
MEMarwan Emara
Marwan Emara
Tamer SalemTamer Salem
Tamer Salem
Immunotherapy has been established as a promising therapy for different cancer types. However, many patients experience primary or secondary resistance to treatment. Immune cells and anti-inflammatory factors are regulated by long noncoding RNAs (lncRNAs). In addition, lncRNAs have a role in immune resistance through antigen presentation loss or attenuation, PD-L1 upregulation, loss of T-cell activities, and activation of G-MDSCs and Tregs in the tumor environment. LncRNAs can also influence the interaction between cancer stem cells and immune cells in the tumor microenvironment, potentially resulting in cancer stem cell resistance to immunotherapy. Immunological-related lncRNAs can influence immune responses either directly by affecting neighboring protein-coding genes or indirectly by sponging miRNAs through various mechanisms. We have emphasized the role and levels of expression of lncRNAs that have been linked to immune cell formation, differentiation, and activation, which may have an influence on immunotherapy efficacy.

Verified
Journal Article
Open access
PDF file
DMDina Mofed
Dina Mofed
MWMohamed Adel Wahba
Mohamed Adel Wahba
Tamer SalemTamer Salem
Tamer Salem
Targeted cancer therapy is a challenging area that includes multiple chemical and biological vehicles. Virus-like particles (VLPs) combine safety and efficacy in their roles as potential vaccines and drug delivery vehicles. In this study, we propose a novel drug delivery system based on HCV-LPs engineered with SP94 and RGD peptides mediated by a specific molecular chaperone (Grp78) associated with cancer drug resistance. The PCR primers were designed for engineering two constructs, SP94-EGFP-CORE-HIS and RGD-EGFP-CORE-HIS, by sequential PCR reactions. The two fragments were cloned into pFastBac Dual under the polyhedrin promoter and then used to produce two recombinant baculoviruses (AcSP94 and AcRGD). The VLP’s expression was optimized by recombinant virus infection with different MOIs, ranging from 1 to 20 MOI. Recombinant VLP2 were purified by Ni-NTA and their sizes and shapes were confirmed with TEM. They were incubated with different types of cells prior to examination using the fluorescence microscope to test the binding specificity. The effect of the overexpression of the Grp78 on the binding affinity of the engineered VLPs was tested in HepG2 and HeLa cells. The protocol optimization revealed that MOI 10 produced the highest fluorescence intensities after 72 h for the two recombinant proteins (SP94-core and RGD-core). Moreover, the binding assay tested on different types of mammalian cells (HeLa, HEK-293T, and HepG2 cells) showed green fluorescence on the periphery of all tested cell lines when using the RGD-core protein; while, the SP94-core protein showed green fluorescence only with the liver cancer cells, HepG2 and HuH7. Overexpression of Grp78 in HepG2 and HeLa cells enhanced the binding efficiency of the engineered VLPs. We confirmed that the SP94 peptide can be specifically used to target liver cancer cells, while the RGD peptide is sufficiently functional for most types of cancer cells. The overexpression of the Grp78 improved the binding capacity of both SP94 and RGD peptides. It is worth noting that the SP94 peptide can function properly as a recombinant peptide, and not only as a chemically conjugated peptide, as heretofore commonly used.

Verified
Journal Article
Open access
PDF file
DMDina Mofed
Dina Mofed
SSSalwa Sabet
Salwa Sabet
ABAhmed A. Baiomy
Ahmed A. Baiomy
Tamer SalemTamer Salem
Tamer Salem
Long non-coding RNAs (lncRNAs) are regulated in cancer cells, including lncRNA MEG3, which is downregulated in Hepatocellular Carcinoma (HCC). In addition, hepatitis C virus (HCV) core proteins are known to dysregulate important cellular pathways that are linked to HCC development. In this study, we were interested in evaluating the overexpression of lncRNA MEG3, either alone or in combination with two forms of HCV core protein (C173 and C191) in HepG2 cells. Cell viability was assessed by MTT assay. Transcripts’ levels of key genes known to be regulated in HCC, such as p53, DNMT1, miRNA152, TGF-b, and BCL-2, were measured by qRT-PCR. Protein expression levels of caspase-3 and MKI67 were determined by immunocytochemistry and apoptosis assays. The co-expression of lncRNA MEG3 and C191 resulted in a marked increase and accumulation of dead cells and a reduction in cell viability. In addition, a marked increase in the expression of tumor suppressor genes (p53 and miRNA152), as well as a marked decrease in the expression of oncogenes (DNMT1, BCL2, and TGF-b), were detected. Moreover, apoptosis assay results revealed a significant increase in total apoptosis (early and late). Finally, immunocytochemistry results detected a significant increase in apoptotic marker caspase-3 and a decrease in tumor marker MKI67. In this study, transgene expression of C191 and lncRNA MEG3 showed induction in apoptosis in HepG2 cells greater than the expression of each one alone. These results suggest potential anticancer characteristics.

23 October 2021
Verified
Conference Paper
Closed access
HAHala S. Abuelmakarem
Hala S. Abuelmakarem
WAWafaa A. Ahmed
Wafaa A. Ahmed
DMDina Mofed
Dina Mofed
MWMohammed Wael
Mohammed Wael
SSSherif A. Sami
Sherif A. Sami
Early cancer detection increases the healing rate according to the cancer stage. Nanotechnology is an advanced technique in cancer management due to the permeability and retention effect. Nano contrast agents are chief in early cancer detection because they diffuse in the cancerous tissue due to permeability and retention. This study aims to synthesize Chitosan Magnetic Nanoparticles (CM NPS) to evaluate them as a contrast agent for cells imaging, in vitro, under near-infrared irradiation. CM NPs were synthesized using the wetted chemical method. They were characterized using Dynamic Light Scattering, High-resolution Transmission Electronic Microscopy (HR- TEM), Fourier Transform Infrared (FTIR) Spectroscopy, and X-ray diffraction (XRD). The shining effect of the CM NPs was evaluated under the inverted microscopy over through a human lung epithelial cell culture in vitro. The characterization results ensured the successful synthesis of CM NPs. The photomicrographs appeared shining light of CM NPs on the cells photographed under the inverted microscope.

1 January 2020 in Journal of Surgery and Research
Verified
Journal Article
Open access
PDF file
SSShon Shmushkevich
Shon Shmushkevich
MBMassimo Baudo
Massimo Baudo
NKNagla Abdel Karim
Nagla Abdel Karim
MMMahmoud Morsi
Mahmoud Morsi
MKMariam Khobsa
Mariam Khobsa
Mohamed RahoumaMohamed Rahouma
Mohamed Rahouma
Objective: To investigate Coronavirus Disease 2019 (COVID-19) associated mortality, the prevalence of different symptoms, and the prevalence and association between comorbidities and their effects on outcomes. Methods: We performed a systematic literature search and meta-analysis on studies that assess COVID-19 patients' symptoms, comorbidities, and outcomes using pooled event rate (PER) and pooled event means (PEM). The primary outcome was the pooled all- cause short-term mortality. The secondary outcomes were length of hospital stay and symptom presentation. Meta-regression and leave-one-out analysis were conducted for mortality. Results: 56 articles met our inclusion criteria with a total of 9074 patients. The PEM for age was 49.6 years. The PER for female gender was 46.79%. The PER for smoking, hypertension, cardiac comorbidities, diabetes was 10.96%, 24.47%, 20.30%; 12.34% respectively. The PER for CAD, COPD, history of cancer and chronic liver disease was 5.44%, 3.96%, 3.75% and 3.08%. The PER for fever, cough, sore throat and headache was 79.29%, 56.48%, 11.10%, 8.16%, respectively. The PER for diarrhea, chest pain, fatigue and vomiting was 11.32%, 13.43%, 27.72% and 11.98%, respectively. PEM for hospital stay was 10.9 days (95% CI 7.3- 16.1 days). The PER for hospital mortality was 11.17% (95% CI, 6.67% - 17.89%). Hospital mortality was significantly and positively associated with cardiac comorbidity and COPD. Age and cancer were not associated with higher hospital mortality. Conclusion: Fever and cough are the most common presenting symptoms with estimated PER of 79.29% and 56.48% respectively. Hospital mortality is significantly and positively associated with cardiac comorbidities, CAD, and COPD, while not being significantly associated with patient age or cancer.